Last reviewed · How we verify
Jaktinib
Jaktinib is a Small molecule drug developed by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. It is currently in Phase 3 development. Also known as: Jaktinib.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Jaktinib |
|---|---|
| Also known as | Jaktinib |
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis (PHASE2)
- Efficacy and Safety of Gecacitinib Hydrochloride in Prophylaxis Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis (NA)
- Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS) (PHASE3)
- A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis (PHASE3)
- First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD) (PHASE1, PHASE2)
- Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (PHASE3)
- Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (PHASE3)
- A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Jaktinib CI brief — competitive landscape report
- Jaktinib updates RSS · CI watch RSS
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd portfolio CI
Frequently asked questions about Jaktinib
What is Jaktinib?
Who makes Jaktinib?
Is Jaktinib also known as anything else?
What development phase is Jaktinib in?
Related
- Manufacturer: Suzhou Zelgen Biopharmaceuticals Co.,Ltd — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Jaktinib
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing